Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2006_021 |
Not provided
Not provided
Not provided
The overall profile does not support development for obesity
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A worldwide study with extension in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug for weight loss on body weight.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Arm 1: MK0364 0.5 mg capsule once daily |
|
| 2 | Experimental | Arm 2: MK0364 1 mg capsule once daily |
|
| 3 | Experimental | Arm 3: MK0364 2 mg capsule once daily |
|
| 4 | Placebo Comparator | Arm 4: Pbo capsule once daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Taranabant | Drug | Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Body weight at 36 weeks, HbA1c at 36 weeks | 36 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Body weight at 24 and 52 weeks, HbA1c at 24 and 52 weeks | 24 and 52 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20518807 | Result | Kipnes MS, Hollander P, Fujioka K, Gantz I, Seck T, Erondu N, Shentu Y, Lu K, Suryawanshi S, Chou M, Johnson-Levonas AO, Heymsfield SB, Shapiro D, Kaufman KD, Amatruda JM. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obes Metab. 2010 Jun;12(6):517-31. doi: 10.1111/j.1463-1326.2009.01188.x. |
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C521311 | N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Comparator: Placebo | Drug | Placebo capsule once daily. Treatment for 52 weeks. |
|
| D004700 | Endocrine System Diseases |